Systemic corticosteroids in critical illness: an evidence-based framework for clinical decision-making.
Yu-Wen Chang, Chun-Fu Chung, Suey-Haur Lee et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review qualitatively synthesized randomized trials, reviews, and meta-analyses to develop a decision framework for systemic corticosteroids in severe community-acquired pneumonia (sCAP), acute respiratory distress syndrome (ARDS), and septic shock. It reports context-specific benefits: early continuous-infusion hydrocortisone significantly reduced 28-day mortality in sCAP; a 10-day dexamethasone regimen improved ventilator-free days and survival in moderate-to-severe ARDS; and early hydrocortisone plus fludrocortisone accelerated shock resolution and lowered 90-day mortality in septic shock. The review emphasizes that efficacy varies by clinical scenario and regimen.
Key findings
- In sCAP, early continuous-infusion hydrocortisone significantly reduced 28-day mortality.
- In moderate-to-severe ARDS, a 10-day dexamethasone regimen improved ventilator-free days and survival.
- In septic shock, early hydrocortisone-fludrocortisone accelerated shock resolution and lowered 90-day mortality.
- The review identifies blood glucose targets of 140-180 mg/dL and monitoring for secondary infections as safety measures.
Why it matters
The synthesis cautions against treating corticosteroids as a uniform class intervention. Reported benefits differ across critical illnesses and regimens, supporting decisions that account for the clinical scenario, timing, and drug profile. Its safety framework also highlights glucose control and surveillance for secondary infection as relevant components of corticosteroid use in critical illness.
What to keep in mind
The review qualitatively synthesizes heterogeneous trials and secondary evidence across three conditions; the abstract provides no pooled effect estimates.